#USA #Richmond #opioid use disorder #Buprenorphine #INDV

New Study on Buprenorphine's Effectiveness

Indivior PLC recently announced groundbreaking findings from a clinical trial published in JAMA Network Open, aimed at addressing the challenges of opioid use disorder (OUD) amid the ongoing opioid crisis. The randomized, double-blind study explored the safety and effectiveness of the medication SUBLOCADE® (extended-release buprenorphine) among participants with moderate-to-severe OUD.

Study Overview

The clinical trial involved participants divided into two groups, receiving either the 100 mg or 300 mg monthly maintenance doses of SUBLOCADE. Throughout the trial, participants showed a remarkable reduction in opioid use, with instances dropping from over 43 per week at the beginning to fewer than 3 by week three, a trend that was maintained up to week 38. Both doses were well tolerated among the participants, with no new safety concerns raised during the study.

Targeted Insights

The study also performed post-hoc analyses, particularly focusing on individuals with high-frequency fentanyl use. The 300 mg dose emerged as significantly more effective for this subset of individuals, who reported higher abstinence rates compared to those receiving the lower dose. This finding highlights the potential of adjusting treatment plans based on specific patient needs, particularly in an era where fentanyl-related risks are prevalent.

Expert Commentary

Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior, shared insights on the importance of these findings. He emphasized that even in cases with high-frequency fentanyl use, extended-release buprenorphine could provide a viable means of enhancing abstinence from opioids. This underscores the necessity for treatment methodologies that are nuanced and capable of adapting to evolving public health challenges.

Safety Considerations

While the results are promising, there are important safety considerations for the use of SUBLOCADE. Injection site reactions were reported more frequently in the 300 mg group but were generally mild to moderate in nature. The study's findings also elucidate the need for monitoring as some risks, such as respiratory depression and the potential for addiction, remain present due to buprenorphine's classification as a Schedule III controlled substance.

Role of SUBLOCADE

SUBLOCADE is specifically indicated for patients with opioid use disorder who have started treatment with a transmucosal buprenorphine product. It is crucial that this treatment is a component of a comprehensive plan that includes counseling and psychosocial support. Notably, due to the serious risks associated with intravenous administration, SUBLOCADE is accessible only through a restricted program, the SUBLOCADE REMS Program, aimed at preventing misuse and ensuring safe delivery.

Conclusion

The findings from this study may change how clinicians approach the treatment of opioid use disorder, particularly for those at high risk due to frequent fentanyl use. As the opioid crisis evolves, innovative therapies like SUBLOCADE may offer hope and a path to recovery for those struggling with addiction. Future studies may further refine these findings and expand the efficacy profile of extended-release buprenorphine, providing critical solutions in the fight against opioid dependency.

For more information, please visit www.indivior.com. Stay connected with Indivior on LinkedIn for the latest updates and research in opioid addiction treatment.